Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy

By R. Finkel, E. Mercuri, B. Darras, A. Connolly, N. Kuntz, J. Kirschner, C. Chiriboga, Kayoko Saito, L. Servais, E. Tizzano and 388 more. New England Journal of Medicine, 2017

1,887 citations recorded by the source corpus.

Subfields: Genetics, Neurology

View Paper: https://www.semanticscholar.org/paper/3cb8180bb3ce9f3c2da5f1683acfc417763dbc4f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. M. Manoharan
2. Martin Egli

Citations in the corpus

• Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019, neutral): “ASObased clinical treatments have demonstrated dramatic success in cases of spinal motor atrophy (Finkel et al., 2017) and are being tested in Huntington’s disease (Tabrizi et al.”
• Chemistry, structure and function of approved oligonucleotide therapeutics (2023, methodology): “SMA is a major genetic disorder associated with degeneration of alpha motor neurons and leading to progressive muscular weakness and atrophy.”